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mentioned a reference that actually indicated that dichotomiza-
tion of the continuous adherence variable was inappropriate.
CONCLUSION: MPR and gap between reﬁlls were the most
commonly used measures of medication adherence. Almost one
third of the studies used dichotomous measures. A medication
adherence of 80% of the therapy was typically indicated as the
cut-point between adherence and non-adherence. There is no
accepted clinical or pharmacological rationale for medication
adherence threshold selection. The use of continuous variables to
measure medication adherence is recommended.
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OBJECTIVE: To examine the impact of copayments or brand
named drug as well as other factors on medication persistence
from a large U.S. employer. METHODS: We analyzed medical
and pharmaceutical claims data from 2002 through 2006 for
new users prescribed a single agent for either three antihyperten-
sive (angiotensin converting enzyme inhibitors, beta blockers,
and calcium blockers) or two anti-diabetic (biguanides and sul-
fonylureas) therapeutic classes. Nonpersistence with medication
was measured using three methods: medication possession ratio
(MPR) <0.8; number of days to the ﬁrst drug coverage gap of
15 days; and number of days to drug discontinuation (90
days gap). Logistic regression and Cox proportional hazard
models were performed to evaluate the association between the
potential risk factors and the likelihood of medication nonper-
sistence. RESULTS: A total of 1422 members with 12 months
claim data following the ﬁrst drug ﬁlled were identiﬁed. Fifty-
four percent were male with a mean age 52.8  8.0 years, and
44% initially used a brand named drug. The logistic regression
results revealed that increasing age per year (OR = 0.966; 95%
CI = 0.952–0.979), PPO (OR = 0.424; CI = 0.261–0.689) or
HMO insurance (OR = 0.440; CI = 0.262–0.739) as compared
to conventional fee for service coverage were less likely to have
MPR < 0.8. Management workers (OR = 1.475; CI = 1.113–
1.954) were more likely to have MPR < 0.8. MPR < 0.8 was not
associated with use of an initial brand named drug, comorbidi-
ties, or health care utilization in the six months prior to initiating
medication therapy. The Cox models showed that the risk for
a gap increased 1.1% (HR = 1.011, CI = 1.004–1.019), and
medication discontinuation increased 0.9% (HR = 1.009,
CI = 1.003–1.014) with each $1 increase in initial drug copay-
ments. CONCLUSION: Younger employees, management
workers, conventional fee for service insurance coverage, and an
increase in initial copayments are factors predictive of greater
risk for noncompliance with medications. These data may be
helpful for employers when making drug beneﬁt design decisions.
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OBJECTIVE: The purpose of this study was to quantify the
extent of nonadherence and to determine the rate of switching
across organ rejection drugs. METHODS: Blinded prescription
data from 35 national retail pharmacy chains was analyzed for
13,250 patients taking sirolimus, cyclosporine, and tacrolimus.
Cumulative drug consumption (total days supply) during the one
year follow up period was employed as the measure of adher-
ence. Kaplan Meier estimates of survival (persistence) curves
were used to assess the time to discontinuation and to calculate
the one-year rate of discontinuation. Baseline patient character-
istics, including age, gender, geographic region, median income,
index quantity dispensed, population density, co-pay, and index
reﬁll and days supply prescribed were analyzed. RESULTS:
Adherence data across these drugs showed that sirolimus,
cyclosporine, and tacrolimus patients on average obtained 5.5
(4.5), 5.2 (5.4), and 6.5 (5.3) ﬁlls, and 170.8 (132.9),
159.2 (163.96), and 194.8 (159.6) days supply of medication
over 12 months, respectively. At day 60, 41% of sirolimus, 44%
of tacrolimus, and 52% of cyclosporine patients discontinued
therapy. After 6 months, 68% of tacrolimus and sirolimus and
77% of cyclosporine patients discontinued therapy. The rate of
switching to another agent was 6.5% for sirolimus, 1.4% for
tacrolimus, and 1.1% for cyclosporine at month 6, and 10.9%,
2.3%, and 1.8% at month 12, respectively. CONCLUSION:
Even though organ transplant drugs are vital for transplant
patients, 68% to 77% of patients discontinue therapy after 6
months. Research has showed that nonadherence to immunosup-
pressive therapy is the leading cause of organ rejection, organ
loss, and death. Efforts to maintain patients on these drugs are
needed in the beginning of and throughout treatment to avoid
organ rejection.
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OBJECTIVE: To determine the demographic, insurance, and
health status predictors of noncompliant cost-cutting behavior
among U.S. adults. METHODS: Data were from quarters one
and two of the 2007 National Health and Wellness Survey
(NHWS), an internet-based study of the health care attitudes,
behaviors, disease states, and outcomes of a demographically
representative sample of adults age 18+. Noncompliant cost-
cutting behaviors were deﬁned as taking less medication than
prescribed, cutting tablets in half, or buying fewer tablets. Logis-
tic regression analysis was used to determine the demographic,
insurance, and health status predictors of noncompliant cost-
cutting behavior. RESULTS: Of the 42,010 NHWS respondents,
12% reported some noncomplaint cost-cutting behavior, more
speciﬁcally 7% reported taking less medication than prescribed,
6% reported cutting tablets in half, and 2% reported buying
fewer tablets. Signiﬁcant predictors of greater likelihood of
noncompliant cost-cutting behavior include being non-white
(OR = 1.182, p < 0.001), having a college degree (OR = 1.094,
p = 0.009), having individual or family insurance purchased
directly (OR = 1.300, p < 0.001), purchasing medications
outside the U.S. (OR = 3.862, p < 0.001), number of physical
comorbid conditions (OR = 1.176, p < 0.001), having a psychi-
atric condition (OR = 1.620, p < 0.001), currently smoke
(OR = 1.137, p < 0.001), and body mass index (OR = 1.006,
p = 0.007). Signiﬁcant predictors of lesser likelihood of noncom-
pliant cost-cutting behavior include age (OR = 0.996, p = 0.001),
having insurance through the Veteran’s Administration
(OR = 0.514, p < 0.001), and having Rx coverage (OR = 0.808,
p < 0.001). Gender, marital status, annual income greater than
$50,000, number of adults in household, and insurance through
employer, Medicaid, or Medicare were not signiﬁcant predictors
of non-compliant cost cutting behavior. CONCLUSION: There
are several signiﬁcant predictors of noncompliant cost-cutting
behavior. Knowing these predictors may help in targeting cost
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